Peter Wrighton-Smith, PhD


Peter was the founder and CEO of Oxford Immunotec, a global immunology focussed in vitro diagnostics company, until 2022.

Peter led Oxford Immunotec from foundation in 2002 through: 5 rounds of venture capital, a NASDAQ IPO in 2013, 2 acquisitions, the divestiture of the company’s clinical laboratory to Quest Diagnostics for $180m, and the eventual sale of the company to Revvity in 2021 for $600m. During that time, he grew the company from 1 to 500 employees and from $0 to $100m of revenue, with sales to over 50 countries and direct sales teams across the US, Europe, China and Japan. Peter also served as a non-executive director of Inivata, a US-UK oncology focussed clinical laboratory using next generation sequencing to inform mutation guided treatment approaches and monitor disease recurrence. Inivata was sold to Neogenomics for $390m in 2021.

Peter earned his Masters in Engineering, Economics and Management from the University of Oxford, followed by a DPhil (PhD) in Medical Engineering also at the University of Oxford.

Peter Wrighton-Smith
Cambridge Epigenetix is now biomodal